Brief: TScan Therapeutics Reports Q2 Loss Per Share Of $7.69

Tscan Therapeutics

19/08/2021 12:29

Aug 19 (Reuters) - TScan Therapeutics Inc  TCRX.O :
    * TSCAN THERAPEUTICS REPORTS SECOND QUARTER 2021 FINANCIAL
RESULTS
AND HIGHLIGHTS RECENT COMPANY PROGRESS
    * Q2 LOSS PER SHARE $7.69
    * IND SUBMISSIONS EXPECTED IN Q4 2021 FOR LEAD LIQUID TUMOR
TCR-T
THERAPY CANDIDATES, TSC-100 AND TSC-101
    * TSCAN THERAPEUTICS - AS OF JUNE 30, 2021, HAD CASH,
EQUIVALENTS
TOTALING $106.2 MILLION, WHICH EXCLUDES GROSS PROCEEDS OF $100
MILLION FROM IPO

Source text for Eikon:  ID:nGNX3t4Gtn 
Further company coverage:  TCRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))